This CME Outfitters symposium at the Crohn’s & Colitis Congress (CCC) 2024, entitled Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD, will feature an expert panel discussion on the science behind cytokine-targeting therapies and will utilize animated 3-D models to discuss therapeutic mechanisms of action (MOAs) of emerging agents, clinical distinctions between therapies, and individualizing treatments for lasting outcomes for patients with IBD.
Jessica R. Allegretti, MD, MPH is an Associate Professor of Medicine at Harvard Medical School in the Division of Gastroenterology, Hepatology and Endoscopy, and is the Medical Director of the Crohn’s and Colitis Center at Brigham and Women’s Hospital, where she built and leads the Clinical Trials Program and Fecal Microbiota Transplant Program. Dr. Allegretti graduated from The Miller School of Medicine at the University of Miami in Miami, Florida, trained in internal medicine at Massachusetts’s General Hospital in Boston, Massachusetts, and completed her gastroenterology fellowship training at Brigham and Women’s Hospital before joining faculty there. She later went on to receive a Master of Public Health degree from the Harvard School of Public Health in Boston, Massachusetts.
Dr. Allegretti is a physician-scientist dedicated to discovering and developing innovative microbiome therapeutics and novel treatments for inflammatory bowel disease (IBD). Her research focus is on the mechanism recurrent C.difficile infection (CDI) and the intersection of CDI and IBD. She has authored more than 100 peer-reviewed publications. She has received funding from the National Institutes of Health (NIH), the American College of Gastroenterology and the Crohn’s and Colitis Foundation. Dr. Allegretti has been featured on Home Box Office (HBO), British Broadcasting Corporation (BBC), Netflix, the New York Times and numerous other media outlets. In 2020, Dr. Allegretti received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis (IBD).
David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.
Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.
Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.
Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). There is a lack of awareness and appreciation of the impact of bowel urgency in patients with CD as it is most commonly associated with ulcerative colitis. Bowel urgency in patients with CD results in emotional and social stress, leading to stigma, feelings of isolation, and impacting all aspects of daily life for patients. Bowel urgency is not widely incorporated into clinical assessment indices or clinical trial endpoints for CD, despite being a pivotal symptom influencing patient health-related QoL (HRQoL) and a potential indicator of uncontrolled intestinal inflammation.
In this CMEO Outfitters live-streamed symposium, expert faculty will discuss recognizing the frequency of bowel urgency in patients with CD and the impact on patient QoL, incorporating assessments for bowel urgency through symptom evaluation, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes, and the faculty will also review real-world patient cases.
Migraine is the most common neurological disorder, and the second most common cause of disability in the world. Despite the enormous cost it exacts on patients, the healthcare system, and the greater economy, migraine remains largely undertreated or un-treated. Racial disparities in treatment and outcomes also persist. Even though migraine prevalence is very similar among White, Black, and Latino/Hispanic groups, Black and Latino/Hispanic patients are less likely to even receive a migraine diagnosis than their White peers. Even after diagnosis, patients face unmet treatment needs. Common medications used to treat migraine attacks are poorly tolerated, contraindicated, or simply ineffective in some patients. Newer disease-process-specific therapies may offer hope to patients for whom traditional therapies are ineffective, poorly tolerated, or contraindicated.
During this educational presentation, migraine experts will share real-world examples of screening, diagnosis, and implementation of appropriate pharmacotherapy factoring in social determinants of health and patient access to care.
